Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform

SAN DIEGO & BERLIN & DURHAM, N.C.–(BUSINESS WIRE)–Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule precision therapeutics for devastating cancers and immune disorders, today announced the acquisition of Tavros Therapeutics, Inc., a precision oncology platform company. Vividion is a wholly owned and independently operating subsidiary of Bayer AG. The
Read More

Allurion Announces Positive Topline Results From AUDACITY Trial

NATICK, Mass.–(BUSINESS WIRE)–Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced topline results from the AUDACITY Food & Drug Administration (FDA) pivotal trial evaluating the safety and efficacy of the Allurion Balloon. The AUDACITY trial is an open-label, multicenter, randomized, controlled study and is the first FDA pivotal trial on an intragastric balloon for weight loss to report primary outcomes beyond 9 months. 550 subjects were random
Read More

Anokion Announces Positive Symptom Data from its Phase 2 Trial Evaluating KAN-101 for the Treatment of Celiac Disease

CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced positive symptom data from its Phase 2 ACeD-it trial evaluating its lead candidate, KAN-101, in individuals with celiac disease. The study data serves as the first symptomatic clinical proof of concept for KAN-101 and its potential as a disease-modifying treatment for celiac disease. KAN-101 ind
Read More

Autobahn Therapeutics Announces Initiation of Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Bipolar Depression

SAN DIEGO–(BUSINESS WIRE)–Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 clinical trial evaluating ABX-002, its highly potent, oral, thyroid hormone beta receptor (TRβ) selective agonist, as an adjunctive treatment in adults with bipolar depression. The Phase 2 trial aims to establish biological and clinical proof-of-concept for ABX-002 in bipol
Read More

ONI Launches Aplo Scope to Revolutionize Single Molecule Super-Resolution Microscopy

SAN DIEGO & OXFORD, England–(BUSINESS WIRE)– #AploScope–ONI (Oxford Nanoimaging), a life science tools company focused on developing super-resolution microscopy, announced today the launch of the Aplo Scope, a single molecule super-resolution microscope that enables scientists to observe and measure molecular interactions within cells and tissues with unparalleled precision. The Aplo Scope addresses a critical challenge in single-molecule research—capturing the intricate details of biological systems in
Read More

MPM BioImpact Announces Promotion of Rami Rahal, Ph.D., to Partner

BOSTON–(BUSINESS WIRE)–MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver transformative therapies to patients, today announced the promotion of Rami Rahal, Ph.D., to Partner. “We are proud to announce Rami’s well-deserved promotion in recognition of the tremendous value he has brought to the public investing team at MPM BioImpact,” said Christiana Bardon, M.D., Managing Partner of MPM BioImpact. “Our goal is to invest in companies
Read More
Top